Plinabulin CIN Prophylaxis: Monotherapy Vs Combination Therapy

Video

Implications for using plinabulin as prophylaxis against chemotherapy-induced neutropenia alone or in combination with other therapies based on data revealed by the Protective-1 and Protective-2 trials.

Andrew D. Seidman, MD: I was setting you up to talk about that trial, Protective-2. TAC [docetaxel, doxorubicin hydrochloride, cyclophosphamide] isn’t a regimen that I use a whole lot. I tend to be more of a fan of sequential anthracycline taxane administration, but it certainly was a regimen that could put plinabulin to the test. Does it add to pegfilgrastim? Do you want to talk about that trial, Joyce? It’s twice the size of Protective-1: 110 patients per arm, 221 patients in that trial.

Joyce O’Shaughnessy, MD: This is a prospective phase 3 trial for FDA approval. The data have been submitted to FDA. Hopefully, there will be a favorable action on that, led by our colleague Doug Blayney in breast cancer. All the patients got pegfilgrastim based on the standard of care. That’s a must-have with TAC [docetaxel, doxorubicin hydrochloride, cyclophosphamide]. Then it was with or without the plinabulin against IV [intravenous] once every 3 weeks. It was superior. And it was superior in terms of multiple parameters. Duration of severe neutropenia was the primary end point as I recall, Andy, and it was superior.

Andrew D. Seidman, MD: Cycle 1 severe neutropenia 21.6% with plinabulin, 46.4% with pegfilgrastim. The ability to avoid that neutrophil vulnerability gap more than doubled, and that was a statistically significant result. The duration, of course, was also shorter. That was highly statistically significant. The attack isn’t a regimen that I use a lot, but it was certainly a good regimen to demonstrate what plinabulin can do.

Joyce O’Shaughnessy, MD: The only reason we don’t use it, Andy, is because of typhlitis. Why is it typhlitis? Because the neutrophils dropped like a rocket and the pegfilgrastim doesn’t protect the patient. TAC [docetaxel, doxorubicin hydrochloride, cyclophosphamide] is a very effective regimen. If it can be used more safely, we’d use it more. I like it for certain patients. In ER [estrogen receptor]–positive breast cancer, it’s quite good. But we didn’t use it because people could die of TAC [docetaxel, doxorubicin hydrochloride, cyclophosphamide], you know what I mean? This is absolutely mind-blowing to me, I must say.

Andrew D. Seidman, MD: There’s also a non-statistically significant, but intriguing, difference in febrile neutropenia. With TAC [docetaxel, doxorubicin hydrochloride, cyclophosphamide] supported by just pegfilgrastim, 13.7% of patients had a febrile neutropenia vs 4.2% with plinabulin. That’s not statistically significant given the numbers, but that’s tripling of the percentage points with pegfilgrastim as compared with plinabulin. There were also fewer hospitalizations.

Joyce O’Shaughnessy, MD: Home run. This is like 1 of those, “I can’t believe this.” The idea of an IV therapy for 30 minutes—basically there’s no toxicity.

Transcript edited for clarity.

Recent Videos
Corey Cutler, MD, MPH, and Hannah Choe, MD, experts on GVHD
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer
Corey Cutler, MD, MPH, and Hannah Choe, MD, experts on GVHD
Corey Cutler, MD, MPH, and Hannah Choe, MD, experts on GVHD
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer
2 KOLs are featured in this program.
2 KOLs are featured in this program.
Hannah Choe, MD, an expert on GVHD
Corey Cutler, MD, MPH, an expert on GVHD